The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
In its second-quarter 2026 investor letter, American Century Investments Focused Dynamic Growth Fund highlighted Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as a newly added position. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops and commercializes medicines to treat various diseases. On September 08, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) closed at $810.31 per share, reflecting a market capitalization of $83.43 billion. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted a one‑month return of 0.19%, while its shares gained 43.84% over the past 52 weeks.
American Century Investments Focused Dynamic Growth Fund stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q2 2026 investor letter:
"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). We've been long-time holders of Regeneron because of what we believed was the strength of its research platform. However, we continued to be disappointed by sluggish commercialization efforts for its macular degeneration treatment. We now believe the stock has limited appreciation potential and preferred to redeploy cash to other investments that we thought were more attractive."
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 63 hedge fund portfolios held Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at the end of the second quarter, down from 72 in the previous quarter. While we acknowledge the potential of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.